MAPK8 and rheumatoid arthritis: Since JNK inhibition has potential for reducing inflammation associated with RA, it is reasonable that JNK inhibitors could be developed as RA therapeutics (Han et al., 2001; Bogoyevitch et al., 2010; Koch et al., 2015).